Status:
RECRUITING
Effects of Antiplatelet and Antioxidant Agents on Drusen Progression: A Pilot, Prospective Cohort Study
Lead Sponsor:
Navamindradhiraj University
Conditions:
Dry Age-related Macular Degeneration
Eligibility:
All Genders
50-85 years
Phase:
PHASE3
Brief Summary
The aim of this clinical trial is to evaluate the effect of low doses of antiplatelet medications (aspirin 81 mg/day or clopidogrel 75 mg/day) with or without a combination of antioxidants (N-acetylcy...
Eligibility Criteria
Inclusion
- Dry AMD with at least 1 large drusen. According to the AREDS study, large drusen have a size of more than 125 micron.
- Patients can evaluate SD-OCT (Spectral domain optical coherence tomography), OCT angiography, and best-corrected visual acuity.
- Age range: 50-85 years
- Patients who have previously used antiplatelet drugs.
Exclusion
- Patient with advanced AMD, such as geographic atrophy, neovascular complications (choroidal neovascularization)
- Patient with additional retinal diseases that affect visual acuity, e.g., retinal detachment, diabetic macular edema.
- Patient with a history of intravitreal anti-VEGF injection or macular laser.
- Patient using SSRIs, SNRIs, azole, NSAIDs, dual antiplatelet, anticoagulant medications.
Key Trial Info
Start Date :
December 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2026
Estimated Enrollment :
174 Patients enrolled
Trial Details
Trial ID
NCT06165068
Start Date
December 1 2023
End Date
September 1 2026
Last Update
December 15 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of ophthalmology, Faculty of medicine, Vajira hospital, Navamindradhiraj University
Bangkok, Dusit, Thailand, 10300